Key facts
- AbOliGo’s last known valuation is $480K (Oct 2024).
- It has raised $200K; the latest was Early Stage VC in Aug 2025.
- Status: Privately Held (backing).
- ·Watchlist + deal alerts for AbOliGo
- ·The full record, as it builds
Funding rounds
No funding rounds for AbOliGo are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About AbOliGo
Developer of antibody-oligonucleotide conjugates designed to enhance protein analysis and proteomics workflows. The company offers rapid and reproducible production of conjugates, enabling researchers to efficiently conduct multiplexed assays, improve detection accuracy, and achieve consistent results in proteomics, spatial biology, and high-throughput screening applications, providing a reliable tool for scientific communities seeking advanced solutions in protein research and diagnostics.
- Sector
- Healthcare
- HQ
- Cambridge, United Kingdom
- Founded
- 2024
- Employees
- 4
- Website
- aboligo.com/
- Ownership
- Privately Held (backing)
AbOliGo doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in AbOliGo shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on AbOliGo in its N-PORT filings yet. We sweep new filings monthly.